Integrated Wealth Concepts LLC Trims Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Integrated Wealth Concepts LLC trimmed its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 4.1% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 4,902 shares of the pharmaceutical company’s stock after selling 207 shares during the period. Integrated Wealth Concepts LLC’s holdings in Vertex Pharmaceuticals were worth $1,974,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. RiverPark Advisors LLC lifted its stake in Vertex Pharmaceuticals by 285.3% in the 4th quarter. RiverPark Advisors LLC now owns 393 shares of the pharmaceutical company’s stock worth $158,000 after purchasing an additional 291 shares in the last quarter. Coppell Advisory Solutions LLC raised its position in shares of Vertex Pharmaceuticals by 137.3% in the fourth quarter. Coppell Advisory Solutions LLC now owns 484 shares of the pharmaceutical company’s stock worth $193,000 after buying an additional 280 shares in the last quarter. MGO One Seven LLC grew its position in Vertex Pharmaceuticals by 68.6% during the fourth quarter. MGO One Seven LLC now owns 5,742 shares of the pharmaceutical company’s stock worth $2,312,000 after buying an additional 2,336 shares in the last quarter. Dark Forest Capital Management LP increased its stake in Vertex Pharmaceuticals by 54.6% in the 4th quarter. Dark Forest Capital Management LP now owns 1,657 shares of the pharmaceutical company’s stock worth $667,000 after acquiring an additional 585 shares during the last quarter. Finally, Alta Advisers Ltd raised its holdings in shares of Vertex Pharmaceuticals by 24.4% in the 4th quarter. Alta Advisers Ltd now owns 871 shares of the pharmaceutical company’s stock valued at $351,000 after acquiring an additional 171 shares in the last quarter. 90.96% of the stock is currently owned by institutional investors.

Insider Activity

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 310 shares of the company’s stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $459.83, for a total transaction of $142,547.30. Following the transaction, the executive vice president now owns 64,021 shares in the company, valued at approximately $29,438,776.43. This represents a 0.48 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP David Altshuler sold 3,231 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $500.00, for a total value of $1,615,500.00. Following the sale, the executive vice president now owns 26,512 shares in the company, valued at $13,256,000. This represents a 10.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 4,315 shares of company stock valued at $2,121,012. Corporate insiders own 0.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on VRTX shares. Wells Fargo & Company lowered Vertex Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $460.00 price objective for the company. in a report on Thursday, January 30th. HC Wainwright reissued a “buy” rating and issued a $550.00 price target on shares of Vertex Pharmaceuticals in a report on Tuesday, February 11th. Barclays upped their target price on shares of Vertex Pharmaceuticals from $435.00 to $467.00 and gave the stock an “equal weight” rating in a research report on Tuesday, February 11th. Cantor Fitzgerald restated an “overweight” rating and set a $535.00 price target on shares of Vertex Pharmaceuticals in a research report on Tuesday, April 22nd. Finally, Canaccord Genuity Group upgraded Vertex Pharmaceuticals from a “sell” rating to a “hold” rating and upped their price objective for the stock from $408.00 to $424.00 in a report on Tuesday, February 11th. Ten analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $514.91.

Vertex Pharmaceuticals Trading Up 0.3 %

VRTX opened at $493.84 on Monday. Vertex Pharmaceuticals Incorporated has a one year low of $377.85 and a one year high of $519.88. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.69 and a quick ratio of 2.35. The business has a 50 day simple moving average of $489.78 and a two-hundred day simple moving average of $466.28. The firm has a market capitalization of $126.81 billion, a price-to-earnings ratio of -224.47, a PEG ratio of 2.11 and a beta of 0.50.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 EPS for the quarter, missing analysts’ consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. Analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.